[go: up one dir, main page]

WO2004097000A3 - Ligand-exchange functional antigens, and use of same in pharmaceutical vaccine compositions - Google Patents

Ligand-exchange functional antigens, and use of same in pharmaceutical vaccine compositions Download PDF

Info

Publication number
WO2004097000A3
WO2004097000A3 PCT/US2004/013169 US2004013169W WO2004097000A3 WO 2004097000 A3 WO2004097000 A3 WO 2004097000A3 US 2004013169 W US2004013169 W US 2004013169W WO 2004097000 A3 WO2004097000 A3 WO 2004097000A3
Authority
WO
WIPO (PCT)
Prior art keywords
ligand
antigens
same
vaccine compositions
exchange functional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/013169
Other languages
French (fr)
Other versions
WO2004097000A2 (en
Inventor
Stanley L Hem
Harm Hogenesch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of WO2004097000A2 publication Critical patent/WO2004097000A2/en
Anticipated expiration legal-status Critical
Publication of WO2004097000A3 publication Critical patent/WO2004097000A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides novel modified, hydroxyl replacing antigens, vaccines including the modified antigens, and related methods. Modified antigens include at least one hydroxyl replacing moiety capable of replacing a surface hydroxyl group of a metal hydroxide adjuvant by ligand exchange to form a metal hydroxide adjuvant/antigen complex.
PCT/US2004/013169 2003-04-29 2004-04-29 Ligand-exchange functional antigens, and use of same in pharmaceutical vaccine compositions Ceased WO2004097000A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46682603P 2003-04-29 2003-04-29
US60/466,826 2003-04-29

Publications (2)

Publication Number Publication Date
WO2004097000A2 WO2004097000A2 (en) 2004-11-11
WO2004097000A3 true WO2004097000A3 (en) 2007-10-04

Family

ID=33418427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013169 Ceased WO2004097000A2 (en) 2003-04-29 2004-04-29 Ligand-exchange functional antigens, and use of same in pharmaceutical vaccine compositions

Country Status (1)

Country Link
WO (1) WO2004097000A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090035326A1 (en) * 2005-11-01 2009-02-05 Novartis Ag Compositions with antigens adsorbed to calcium phosphate
WO2018069520A1 (en) * 2016-10-14 2018-04-19 Brenntag Biosector A.S. Modified mineral micro-particles, methods of preparing the same and uses thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US11224648B2 (en) 2017-12-19 2022-01-18 Massachusetts Institute Of Technology Antigen-adjuvant coupling reagents and methods of use
WO2020263399A1 (en) * 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
CN114028559B (en) * 2021-12-28 2024-06-18 广东粤港澳大湾区国家纳米科技创新研究院 Aluminum-manganese composite nanocrystal and its preparation method and application

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHANG ET AL.: "Role of the Electrostatic Attractive Force in the Adsorption of Proteins by Aluminum Hydroxide Adjuvant", PDA JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, vol. 51, 1997, pages 25 - 29, XP009005780 *
HOGENESCH: "Mechanisms of stimulation of the immune reponse by aluminum adjuvants", VACCINE, vol. 20, 2002, pages S34 - S39, XP004361371 *
IYER ET AL.: "Effect of the degree of phosphate substitution in aluminium hydroxide adjuvant on the adsorption of phosphorylated proteins", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol. 8, no. 1, 2003, pages 81 - 86 *
IYER ET AL.: "Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production", VACCINE, vol. 21, 2003, pages 1219 - 1223, XP004404300 *
RINELLA ET AL.: "Effects of Anions on Model Aluminum-Adjuvant-Containing Vaccines", JOURNAL OF COLLOID AND INTERFACE SCIENCE, vol. 172, 1995, pages 121 - 130 *
SHI ET AL.: "Change in the degree of adsorption of proteins by aluminum-containing adjuvants following exposure to interstitial fluid", VACCINES, vol. 20, 2002, pages 80 - 85, XP004305117 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Also Published As

Publication number Publication date
WO2004097000A2 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2000050075A3 (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
EP2181714A3 (en) Immunogenic composition for use in vaccination against staphylococcei
GB0025577D0 (en) Vaccine
BR0310042A (en) Mucosal combination vaccines for bacterial meningitis
TW200722101A (en) Novel composition
WO2007068907A3 (en) Vaccine compositions comprising a saponin adjuvant
GB0428394D0 (en) Saccharide conjugate vaccines
GB2434367A (en) Improved vaccines
JP2007538044A5 (en)
WO2006126981A3 (en) Compositions and methods for mucosal vaccination
DE602005023422D1 (en) CONJUGATE
WO2007105115A3 (en) Compositions and methods for immunisation using cd1d ligands
WO2005105139A3 (en) Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy
FR2922767B1 (en) PROCESS FOR PREPARING A VACCINE COMPOSITION COMPRISING AT LEAST ONE ANTIGEN AND AT LEAST ONE ADJUVANT
WO2006004390A3 (en) Preparation and use of a bivalent vaccine against morphine-heroin addiction
WO2004097000A3 (en) Ligand-exchange functional antigens, and use of same in pharmaceutical vaccine compositions
WO2005120564A3 (en) Vaccine compositions and methods
WO2007146359A3 (en) Sea lice antigen vaccines
MY127452A (en) Vaccines.
WO2005021033A3 (en) Vaccine
WO2005122739A3 (en) Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
WO2007034166A3 (en) Adjuvanted vaccine
WO2005123112A3 (en) Method of enhancing the immune response to a vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase